Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Loss-of-function variants in myocardin cause congenital megabladder in humans and mice
Arjan C. Houweling, … , Adrian S. Woolf, Esther E. Creemers
Arjan C. Houweling, … , Adrian S. Woolf, Esther E. Creemers
Published September 12, 2019
Citation Information: J Clin Invest. 2019;129(12):5374-5380. https://doi.org/10.1172/JCI128545.
View: Text | PDF
Concise Communication Muscle biology Article has an altmetric score of 17

Loss-of-function variants in myocardin cause congenital megabladder in humans and mice

  • Text
  • PDF
Abstract

Myocardin (MYOCD) is the founding member of a class of transcriptional coactivators that bind the serum-response factor to activate gene expression programs critical in smooth muscle (SM) and cardiac muscle development. Insights into the molecular functions of MYOCD have been obtained from cell culture studies, and to date, knowledge about in vivo roles of MYOCD comes exclusively from experimental animals. Here, we defined an often lethal congenital human disease associated with inheritance of pathogenic MYOCD variants. This disease manifested as a massively dilated urinary bladder, or megabladder, with disrupted SM in its wall. We provided evidence that monoallelic loss-of-function variants in MYOCD caused congenital megabladder in males only, whereas biallelic variants were associated with disease in both sexes, with a phenotype additionally involving the cardiovascular system. These results were supported by cosegregation of MYOCD variants with the phenotype in 4 unrelated families by in vitro transactivation studies in which pathogenic variants resulted in abrogated SM gene expression and by the finding of megabladder in 2 distinct mouse models with reduced Myocd activity. In conclusion, we have demonstrated that variants in MYOCD result in human disease, and the collective findings highlight a vital role for MYOCD in mammalian organogenesis.

Authors

Arjan C. Houweling, Glenda M. Beaman, Alex V. Postma, T. Blair Gainous, Klaske D. Lichtenbelt, Francesco Brancati, Filipa M. Lopes, Ingeborg van der Made, Abeltje M. Polstra, Michael L. Robinson, Kevin D. Wright, Jamie M. Ellingford, Ashley R. Jackson, Eline Overwater, Rita Genesio, Silvio Romano, Letizia Camerota, Emanuela D’Angelo, Elizabeth J. Meijers-Heijboer, Vincent M. Christoffels, Kirk M. McHugh, Brian L. Black, William G. Newman, Adrian S. Woolf, Esther E. Creemers

×

Figure 3

MYOCD mutations abrogate activation of SM cell gene expression in vitro.

Options: View larger image (or click on image) Download as PowerPoint

MYOCD mutations abrogate activation of SM cell gene expression in vitro...
(A) Mouse fibroblasts were transiently transfected for 48 hours with expression vectors for MYOCD or the indicated MYOCD mutants (mutation A1: p.S229Qfs*17; mutation A2: p.E530G; mutation B: p.R115*) and a luciferase reporter linked to the Transgelin (Sm22) promoter (n = 3/group). (B) Mouse fibroblasts were transfected with expression plasmids encoding MYOCD or the indicated mutants (n = 4/group). An empty expression plasmid served as a control. RNA was isolated, and SM gene expression was measured by qPCR. GAPDH was used to normalize expression. Overexpression levels of MYOCD were comparable between conditions (Supplemental Figure 3). *P < 0.01 compared with WT MYOCD according to 1-way ANOVA with Dunnett’s multiple comparison test. Shown are representative experiments of 2 independent repeats.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts

Blogged by 1
Posted by 11 X users
Reddited by 2
23 readers on Mendeley
See more details